Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology

NACompletedINTERVENTIONAL
Enrollment

458

Participants

Timeline

Start Date

May 7, 2018

Primary Completion Date

January 28, 2020

Study Completion Date

March 12, 2021

Conditions
Atrial Fibrillation
Interventions
DEVICE

WATCHMAN FLX

Left atrial appendage closure with WATCHMAN FLX

Trial Locations (29)

10016

New York University Medical Center, New York

10029

Mt. Sinai School of Medicine, New York

17403

York Hospital, York

20010

Washington Hospital Center, Washington D.C.

23219

Virginia Commonwealth University Health System, Richmond

23507

Sentara Norfolk General Hospital, Norfolk

30308

Emory University, Atlanta

32308

Tallahassee Memorial Hospital, Tallahassee

35243

Grandview Medical Center, Birmingham

37232

Vanderbilt University Medical Center, Nashville

38801

Cardiology Associates of N. Mississippi, Tupelo

44195

Cleveland Clinic, Cleveland

48202

Henry Ford Hospital, Detroit

55102

HealthEast St. Joseph's Hospital, Saint Paul

55902

Mayo Clinic, Rochester

64111

St. Luke's Hospital, Kansas City

72401

Nair Research, LLC, Jonesboro

78705

Texas Cardiac Arrhythmia, Austin

85006

Phoenix Cardiovascular Research Group, Phoenix

85016

St. Joseph's Hospital & Medical Center, Phoenix

90048

Cedars-Sinai Medical Center, Los Angeles

90404

St. John's Hospital / Pacific Heart, Santa Monica

92037

Scripps Green, La Jolla

92121

Sharpe Chula Vista Medical Center, San Diego

97227

Legacy Emanuel Hospital & Health Center, Portland

98664

PeaceHealth Southwest Medical, Vancouver

02114

Massachusetts General Hospital, Boston

03102

Catholic Medical Center, Manchester

08080

Cardiovascular Associates of the Delaware Valley, Sewell

Sponsors
All Listed Sponsors
lead

Boston Scientific Corporation

INDUSTRY

NCT02702271 - Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology | Biotech Hunter | Biotech Hunter